Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer by Yulin Wang, Yunjie Yang, Binghong Guo, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang

Subjects: “…structural domains of BRCA mutations…”
Get full text

Prognostic factors in hereditary breast cancer: A review by Ziske Maritska, Sarmoko

“…However, the risk of developing other malignancies, such as ovarian cancer and melanoma, remains elevated in BRCA mutation carriers. Studies show a significant variation in survival rates, with BRCA mutation carriers having lower overall survival compared to non-carriers. …”
Get full text

Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer by Trudy J. Philips, Britt K. Erickson, Stefani N. Thomas

“…However, recent studies have shown that some epithelial ovarian tumors respond to PARP inhibitors irrespective of their HRD or BRCA mutation status. An exclusive focus on the genome overlooks the significant insight that can be gained from other biological analytes, including proteins, which carry out cellular functions. …”
Get full text

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis by Shiya Ji, Lu Chen, Yebo Yu, Xupeng Chen, Liwen Wei, Lili Gou, Cheng Shi, Susu Zhuang

“…Results Six randomized controlled trials were examined and the four PARPis (olaparib, niraparib, rucaparib and fuluzolparib) have been found to significantly increase the PFS in entire population as well as in subgroups of HRD and BRCAm (BRCA mutation). Only olaparib demonstrated a substantial improvement in OS compared to placebo in entire population (hazard ratio [HR] 0.73; 95% confidence interval [CI] 0.60–0.90), as well as in the subgroup of BRCAm. …”
Get full text

Homologous recombination deficiency test validation in patients with high-grade advanced ovarian cancer by Angelica Nogueira Rodrigues, Andreza Karine de Barros Almeida Souto, Diocésio Alves Pinto de Andrade, Larissa Müller Gomes, Sandra Satie Koide, Renata de Godoy e Silva, Bruno Batista de Souza, Juliana Doblas Massaro, Andréia Cristina de Melo, Andrea Morais Borges, Camila Giro, Carlos Augusto Vasconcelos de Andrade, Cesar Martins da Costa, Daniel Luiz Gimenes, Eduardo Caminha Bandeira de Mello, Fernanda Cesar de Oliveira, Frederico Müller de Toledo Lima, Gabriel Lima Lopes, Gustavo de Oliveira Bretas, Gustavo Guerra Jacob, Herika Lucia da Costa Silva, Juliana Ferrari Notaro, Lara Ladislau Alves, Marcos Veloso Moitinho, Mirian Cristina da Silva, Roberto Abramoff, Thais Amaral da Cunha Rauber, Rodrigo Dienstmann, Fernanda Christtanini Koyama

“…BackgroundAlong with BRCA mutation status, homologous recombination deficiency (HRD) testing is a prognostic and predictive biomarker for poly-ADP-ribose polymerase (PARP) inhibitor therapy indication in high-grade epithelial ovarian, fallopian tube, or peritoneal cancer. …”
Get full text

Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population by Dione Aguilar, María Lourdes Garza-Rodríguez, Carolina Elizabeth Muñiz-Garza, Fernando Alcorta Nuñez, Cynthia Mayte Villarreal-Garza, Oscar Vidal-Gutiérrez, Diana Cristina Pérez-Ibave, Carlos Horacio Burciaga-Flores

“…The optimal approach to cancer treatment for non-BRCA mutation carriers warrants further investigation to develop newer therapies.…”
Get full text

PARP Inhibitors in the Treatment of Ovarian Cancer by Andrzej Paweł Zuzak, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska

“…Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. …”
Get full text

The relationship between HYDIN and fallopian tubal cilia loss in patients with epithelial ovarian cancer by Yuanli Guo, Yuanli Guo, Xinxin He, Junfeng Liu, Yanming Tan, Chao Zhang, Shan Chen, Shan Chen, Sheng Zhang

“…Several studies have demonstrated that women with BRCA mutations have, on average, 50% fewer ciliated cells compared with general women. …”
Get full text

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study by Mohamed Aseafan, Ali H. Alfakeeh, Emad Tashkandi, Mervat Mahrous, Mohammed Alghamdi, Bader Alshamsan, Marwan Al-Hajeili, Safwan Bakhsh, Kanan Alshammari, Fahad A. Almugbel, Abdulhameed H. Alfagih, Ahmed Allehebi, Mohamed Montaser, Mohamed Hamdy Elsafty, Khaled Abd Elaziz Elnaghi, Ibrahim Issa, Eesa Bakshi, Sadeem AlSubaie, Bandar AlMutairi, Hoda Mokhtar, Mohamed Aboelatta, Nedal Bukhari, Ali M. Alzahrani, Tusneem Elhassan, Ali Alqahtani, Shouki Bazarbashi

“…Among patients tested, 7.1% had deficient mismatch repair (d-MMR), and 5.8% harbored BRCA mutations. Conclusions This real-world study confirms that clinical outcomes for locally advanced unresectable and metastatic PDAC in Saudi Arabia are consistent with international data, with FOLFIRINOX showing superior outcomes over gemcitabine-based regimens. …”
Get full text

Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors by Romain Pacaud, Scott Thomas, Sibapriya Chaudhuri, Ann Lazar, Luika A. Timmerman, Pamela N. Munster

“…In animal studies, our BRCA-engineered hypomorphs and several independent PDX models with clinically relevant BRCA mutations were acutely more vulnerable to this drug combination. …”
Get full text

Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair by Min-ah Kim, Banseok Kim, Jihyeon Jeon, Jonghyun Lee, Hyeji Jang, Minjae Baek, Sang-Uk Seo, Dongkwan Shin, Anindya Dutta, Kyung Yong Lee

“…Given that DSBs are highly cytotoxic, PARP inhibitors (PARPi), a prominent class of anticancer drugs, are designed to target tumors with HR deficiency (HRD), such as those harboring BRCA mutations. However, many tumor cells acquire resistance to PARPi, often by restoring HR in HRD cells through the inactivation of NHEJ. …”
Get full text